Key result
Amiodarone effectively reduces excitability and slows conduction in Wolff-Parkinson-White syndrome, offering an alternative to surgery despite its high incidence of side effects and long half-life.
Why the study?
Does amiodarone improve management of Wolff-Parkinson-White syndrome?
Does amiodarone improve management of Wolff-Parkinson-White syndrome?
Answers are grounded in this paper and cite their sources.
Amiodarone is an effective alternative to surgery for WPW syndrome, though its use requires caution due to significant side effects and a long half-life.
The ayitiarrhythmic properties of amiodarone in WPW‐syndrome depend on several simultaneously active mechanisms. Its electrophysiologic properties lead to reduction of excitabUity, lengthening of refractory periods and slowing of conduction. With these effects, it reduces premature ectopic beats and thus initiating events for tachycardias. The ventricular response during atrial fibrillation will be reduced in most but unfor‐tunately not all patients and tachycardia cycle length will be prolonged. Therefore amiodarone seems to be the drug of choice in WPW‐syndrome if there was not a high incidence of side‐effects and an extremely long tissue half‐life. The prescription has therefore to be made with caution since if once applied, its effects are not immediately renersible. Hoioever, in some cases it offers an alternative for surgery of IVPW.
No takes yet. Share an insight, caveat, or question.
Lukas Kappenberger (1986) conducted a review in Wolff-Parkinson-White Syndrome. Amiodarone was evaluated. Amiodarone effectively reduces excitability and slows conduction in Wolff-Parkinson-White syndrome, offering an alternative to surgery despite its high incidence of side effects and long half-life.
Synapse has enriched 10 related papers. Consider them for comparative context: